Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 599 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Next Day Clinic Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

NCT03289832
View directory record Official record
Conditions
Healthy Adults
Interventions
Crucera-SGS, Meriva 500-SF
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

NCT01752426
View directory record Official record
Conditions
Leukemia
Interventions
Heavy Water (2H2O), PCI-32765
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Not applicable Interventional Results available

Emergency Medicine Palliative Care Access

NCT03325985
View directory record Official record
Conditions
Advanced Cancer, End Stage Organ Failure
Interventions
Nurse-led telephonic case management, Facilitated,outpatient specialty palliative care
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
1,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 5, 2026, 5:18 PM EDT
Terminated Not applicable Interventional Results available

Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

NCT00849810
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Nebivolol
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Not applicable Interventional

Eccentric Exercise Versus Eccentric Exercise and Astym for Insertional Achilles Tendinopathy

NCT01988155
View directory record Official record
Conditions
Insertional Achilles Tendinopathy
Interventions
Eccentric Exercise, Astym
Other
Lead sponsor
Indiana University Health Ball Memorial Hospital Rehabiliation Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Muncie, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 5, 2026, 5:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

NCT02457910
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 5, 2026, 5:18 PM EDT
Active, not recruiting No phase listed Observational

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

NCT05508984
View directory record Official record
Conditions
Breast Cancer
Interventions
Amma Cooling Caps
Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Newberg, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 5, 2026, 5:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

NCT05121038
View directory record Official record
Conditions
Colon Cancer, Pancreas Cancer, Digestive Cancer
Interventions
CEND-1, Panitumumab, Folfirinox
Drug
Lead sponsor
Anup Kasi
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 5, 2026, 5:18 PM EDT
Recruiting Phase 4 Interventional

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start

NCT05444582
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel 52 MG Intrauterine System
Drug
Lead sponsor
University of Utah
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Jose, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 5, 2026, 5:18 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 5, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

NCT05743517
View directory record Official record
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Cervix Cancer, Vulvar Cancer, Vaginal Cancer
Interventions
Fit4Treatment
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Red Blood Cell (RBC) Survival Following Transfusion in Infants

NCT00731588
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
Biological
Lead sponsor
John A Widness
Other
Eligibility
1 Hour to 6 Months
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Results available

Neural Mechanisms of Disulfiram Effects

NCT02735577
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Disulfiram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 5, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treatment Optimization of Brain-injured Warfighters

NCT06561100
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Sub-symptomatic Adaptable Exercise Treatment (SAET), Stretching Control Group (SCG)
Behavioral
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Camp Pendleton, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992
View directory record Official record
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
38
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 5, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional Results available

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

NCT01900730
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Valproic Acid (VPA), Questionnaires, Pill Diary, Drainage Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 5, 2026, 5:18 PM EDT
Terminated Phase 4 Interventional

Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study

NCT00771862
View directory record Official record
Conditions
Amputation, Phantom Limb Pain, Stump Pain
Interventions
perineural ropivicaine
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Results available

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

NCT04090190
View directory record Official record
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Not applicable Interventional Results available

Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty

NCT02597673
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Home Exercise Program (HEP), NMES, TENS
Other · Device
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 45 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Campbell North, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Not applicable Interventional

Can a Rapid 2 Day Followup After Discharge From the ED Reduce Readmissions and Death for Patients 75 Years and Older?

NCT01769495
View directory record Official record
Conditions
Emergencies
Interventions
2-3 day return appointment
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
75 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 5, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

NCT00444912
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
G-CSF plus plerixafor, rituximab
Drug · Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 5, 2026, 5:18 PM EDT
Not listed No phase listed Observational

Physical Activity Monitoring in Myasthenia Gravis

NCT06277830
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Wearable sensor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 5, 2026, 5:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 5:18 PM EDT